21Shares Sui ETF 8-K

What Happened

• 21Shares US LLC (the Sponsor) filed an 8-K on July 7, 2026 announcing it gave notice on June 30, 2026 to terminate the Pricing Benchmark Licensing Agreement with CF Benchmarks Ltd., effective August 31, 2026.
• The agreement covered use of the “CME CF Sui — Dollar Reference Rate — New York Variant” Pricing Benchmark, which is used to value the Trust’s shares and to calculate the Trust’s net asset value (NAV).
• The Sponsor said it intends to enter a licensing agreement with FTSE International Limited on or about August 24, 2026 to provide FTSE index data under similar licensing terms.

Key Details

• Termination notice date: June 30, 2026; termination effective: August 31, 2026.
• Current benchmark: CME CF Sui — Dollar Reference Rate — New York Variant (administered by CF Benchmarks).
• New provider: FTSE International Limited; anticipated license start on or about August 24, 2026.
• Licenses described as non-exclusive, non-transferable, non‑sub‑licensable; CF Benchmarks and FTSE are unaffiliated with the Sponsor. No financial terms disclosed.

Why It Matters

• The filing notifies investors that the data source used to value the ETF and calculate NAV will change from CF Benchmarks to FTSE. That is an operational change in how the Trust obtains benchmark data but the 8-K does not state any change to investment strategy, fees, or valuation methodology beyond the provider switch.
• Investors should be aware of the timing (late August 2026) and monitor future disclosures for any updates about implementation, potential short-term pricing effects, or details about the FTSE data used.